Affiliation: Rush University Medical Center
- Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung CancerJordi Tauler
Section of Medical Oncology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA
PPAR Res 2008:750238. 2008..Exploring the function of PPARgamma, in this new context, may provide a better mechanistic model of its role in cancer and give an opportunity to design a more efficient therapeutic approach in combination with LOX/COX inhibitors...
- Lung cancer and inflammation: interaction of chemokines and hnRNPsJordi Tauler
Department of Internal Medicine, Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA
Curr Opin Pharmacol 9:384-8. 2009....
- hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell linesJordi Tauler
Laboratory of Lung Cancer Biology, Section of Medical Oncology, Rush University Medical Center, Chicago, Illinois 60612, USA
Cancer Res 70:7137-47. 2010..These data suggest that expression of hnRNP A2/B1 may play a role in EMT, in nonepithelial lung cancer cell lines A549 and H1703, through the regulation of E-cadherin expression...
- Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancerGeraldine Chow
Lung Cancer Biology Laboratory, Department of Biochemistry, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA
J Biomed Biotechnol 2010:485468. 2010..Together, these results suggest that elevated HA production is able to induce EMT and increase resistance to Iressa in NSCLC. Therefore, regulation of HA level in NSCLC may be a new target for therapeutic intervention...